Hengrui Medicine
Overview
Hengrui Medicine (恒瑞医药, Jiangsu Hengrui Medicine Co., Ltd.) is China's largest innovative pharmaceutical company, headquartered in Lianyungang, Jiangsu Province. Founded in 1970, the company initially focused on generic drug production but shifted to innovative drug R&D in the 2000s. It has since grown into a globally competitive enterprise in areas such as anticancer drugs, anesthetics, contrast agents, and metabolic disease treatments. Notably, it has developed several innovative drugs, including the immune checkpoint inhibitor (PD-1 inhibitor) Camrelizumab, solidifying its position as China's top pharmaceutical company. In recent years, it has accelerated its global market expansion.
Main Content
History and Development
Hengrui Medicine was established in 1970 as a state-owned pharmaceutical factory, primarily producing antibiotics and general medicines until the 1990s. After listing on the Shanghai Stock Exchange in 2000 (600276.SH), it significantly increased R&D investment, transforming into an innovative pharmaceutical company. From the mid-2010s, it expanded its international presence by signing technology transfer and joint development agreements with global pharmaceutical companies.
Key Products and Pipeline
Hengrui Medicine's core product portfolio is broadly divided into three categories.
- Anticancer Drugs: The PD-1 inhibitor Camrelizumab (brand name: Ailikay 艾瑞卡) has received NMPA approval for multiple indications, including hepatocellular carcinoma, esophageal cancer, and non-small cell lung cancer. It also holds various targeted anticancer drugs such as CDK4/6 inhibitors, PARP inhibitors, and HER2 ADCs.
- Anesthetics and Analgesics: It holds the top market share in China for anesthetic drugs like propofol and remifentanil.
- Metabolic Diseases and Others: Diabetes treatments (DPP-4 inhibitors, SGLT2 inhibitors) and contrast agents are also major revenue sources.
Research and Development (R&D) Strategy
Hengrui Medicine invests over 20% of its revenue in R&D, with R&D costs reaching approximately 60 billion RMB (about 8.3 billion USD) as of 2023. It employs over 4,000 researchers in China and operates research institutes in the United States and Europe. It particularly excels in the ADC (antibody-drug conjugate) field, signing successive licensing-out agreements with global big pharma.
Global Licensing-Out
Since the 2020s, Hengrui Medicine has actively pursued technology export agreements with global pharmaceutical companies. Notably, in 2023, after regaining some global rights to Camrelizumab from U.S. pharmaceutical company Eli Lilly, it is conducting global clinical trials independently. In 2024, it signed a technology transfer agreement for its HER2 ADC candidate with a global pharmaceutical company, closing a mega-deal with a total contract value reaching billions of dollars.
Financial Status
As of 2023, Hengrui Medicine reported annual revenue of approximately 230 billion RMB (about 32 billion USD) and net profit of about 45 billion RMB, maintaining stable growth. While heavily reliant on the Chinese domestic market, its overseas revenue share is gradually increasing with global expansion.
Latest Trends
From 2024 to 2025, Hengrui Medicine has shown the following key changes and trends.
- Focused Investment in ADC: Hengrui Medicine is concentrating on developing ADCs (antibody-drug conjugates), which are gaining attention as next-generation cancer therapies. In 2024, several ADC candidates entered global Phase 2 and Phase 3 clinical trials, with TROP2 ADC and HER3 ADC particularly drawing interest.
- Expansion of Global Clinical Trials: Moving beyond China-centric clinical trials, the company is significantly expanding multinational clinical trials targeting U.S. FDA and European EMA approvals. In 2025, it is preparing to submit a U.S. marketing application for Camrelizumab.
- Partnerships and M&A: Alongside strengthening in-house R&D capabilities, Hengrui Medicine is expanding its drug pipeline through strategic alliances with global big pharma. In 2024, it signed a joint research agreement with a U.S. biotech company to enter mRNA-based therapy development.
- Chinese Government Support for the Pharmaceutical Industry: Under the 'Healthy China 2030' policy, the Chinese government actively supports the innovative pharmaceutical industry. Hengrui Medicine benefits from these policies, receiving R&D tax incentives and expedited new drug approvals.
- Intensifying Competition: Competition is intensifying in China with companies like BeiGene and Jiangsu Nhwa, while globally, it faces competition from multinational pharmaceutical companies such as Merck (MSD) and BMS.
Related Topics
- [[Chinese pharmaceutical industry]]
- [[Immune checkpoint inhibitor]]
- [[Antibody-drug conjugate (ADC)]]
- [[Eli Lilly]]
- [[BeiGene]]
---
AI-generated document · Improved by the community